Medicinal products obtained from living cells in\ncomplex biotechnological processes nowadays play a central role in the therapy\nand diagnosis of diseases such as cancer and diabetes.<\/p>\n\n\n\n
Interferons, monoclonal antibodies, coagulation\nfactors, and insulin and other hormones are examples of these products, which\nare known collectively as biologicals. In contrast to standard chemical\nproducts, these medicines consist of several highly complex large molecules and\ncan be extremely sensitive to changes (for example of temperature or the composition\nof the nutrient medium) during their manufacture. The manufacture of\nbiologicals is a technically demanding and intricate operation.<\/p>\n\n\n\n
For some years now, Switzerland has also been\nauthorising biosimilars \u2013 imitations of the original biologicals \u2013 once the\npatent on the original product has expired. Unlike copies of chemical medicines\n(generics), biosimilars are never entirely identical to the original active\nsubstance but only similar to the original, hence the name biosimilar.\nBiosimilars are not generics. The procedure used to authorise them is therefore\nmore complex and requires more surveillance measures than for standard\ngenerics.<\/p>\n","protected":false},"excerpt":{"rendered":"
Medicinal products obtained from living cells in complex biotechnological processes nowadays play a central role in the therapy and diagnosis of diseases such as cancer and diabetes. Interferons, monoclonal antibodies, coagulation factors, and insulin and other hormones are examples of these products, which are known collectively as biologicals. In contrast to standard chemical products, these […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":4202,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"page-templates\/unterthema.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-4082","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n